

Anti-CD7 Antibody (GrisnilimAb)

Introduction

Grisnilimab (WT1), an IgG2a monoclonal antibody (anti-CD7), is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab modulates the transcription of multiple target genes and may be involved in post-transcriptional processing of RNA.

Product parameters

Alternative Names	Grisnilimab setaritox
Target Accession	P09564
Target	CD7
CAS number	2367001-70-3
Molecular Weight	144.72 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

